2 withdrawn, 1 not yet recruiting. 3 Phase 2, 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Withdrawn 2, Not yet recruiting 1 |
| Phase 1 | 2 | Withdrawn 2 |
Follow F2G Ltd: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase II Randomized Study to Evaluate Measures for Endpoint Derivation in Patients With Progressive or Refractory Disseminated Coccidioidomycosis Treated With Olorofim Plus Baseline Standard of Care or Placebo Plus Baseline Standard of Care Olorofim, Placebo - Coccidioidomycosis, Disseminated Fungal Infection | Phase 2 | Not yet recruiting | F2G Ltd | 50 | 2026-12-01 | 2026-09-22 |
| Study on Safety and Pharmacokinetics of Intravenous F901318 for Fungal Prophylaxis in AML Patients F901318, Caspofungin - Pulmonary Aspergillosis - Invasive, Acute Myeloid Leukemia | Phase 1 / Phase 2 | Withdrawn | F2G Ltd | 2017-04-20 | 2018-02-15 | |
| Safety and Pharmacokinetics of Oral F901318 (Fluconazole and Posaconazole) IN Aml Leukaemia F901318 with fluconazole low dose, F901318 with fluconazole high dose, F901318 with posaconazole - Acute Myeloid Leukemia | Phase 1 / Phase 2 | Withdrawn | F2G Ltd | 2017-03-01 | 2018-02-15 |
Leukemia, Myeloid, Acute (2) · Coccidioidomycosis (1) · Invasive Fungal Infections (1) · Invasive Pulmonary Aspergillosis (1) · Mycoses (1)
olorofim (3) · Caspofungin (1) · Fluconazole (1) · posaconazole (1)
George R. Thompson, MD (1) · Oliver A Cornely, MD (1) · Oliver Cornely, PhD, MD (1)